Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9.
A random mutagenesis technique was used to predict the evolutionary potential of beta-lactamase CTX-M-9 toward the acquisition of improved catalytic activity against ceftazidime. Thirty CTX-M mutants were obtained during three rounds of mutagenesis. These mutants conferred 1- to 128-fold-higher MICs of ceftazidime than the parental enzyme CTX-M-9. The CTX-M mutants contained one to six amino acid substitutions. Mutants harbored the substitutions Asp240Gly and Pro167Ser, which were previously observed in clinical CTX-M enzymes. Additional substitutions, notably Arg164His, Asp179Gly, and Arg276Ser, were observed near the active site. The kinetic constants of the three most active mutants revealed two distinct ways of improving catalytic efficiency against ceftazidime. One enzyme had a 17-fold-higher k(cat) value than CTX-M-9 against ceftazidime. The other two had 75- to 300-fold-lower Km values than CTX-M-9 against ceftazidime. The current emergence of CTX-M beta-lactamases with improved activity against ceftazidime may therefore be the beginning of an evolutionary process which might subsequently generate a great diversity of CTX-M-type ceftazidimases.
Delmas
J
J
Laboratoire de Bactériologie, Faculté de Médecine, Centre Hospitalo-Universitaire, Clermont-Ferrand, France. julien.delmas@u-clermont1.fr
Robin
F
F
Carvalho
F
F
Mongaret
C
C
Bonnet
R
R
D002442:Ceftazidime / Q000494:pharmacology*; D018550:Cephalosporin Resistance; D004926:Escherichia coli / Q000187:drug effects; D029968:Escherichia coli Proteins / Q000737:chemistry / Q000235:genetics*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D017422:Sequence Analysis, DNA; D013329:Structure-Activity Relationship; D001618:beta-Lactamases / Q000737:chemistry / Q000235:genetics*; D047090:beta-Lactams / Q000494:pharmacology
D029968:Escherichia coli Proteins; D047090:beta-Lactams; D002442:Ceftazidime; C412613:CTX-M-9 protein, E coli; D001618:beta-Lactamases